Joon Lee
Stock Analyst at Truist Securities
(4.60)
# 116
Out of 4,818 analysts
118
Total ratings
53.77%
Success rate
34.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Buy | $65 → $21 | $9.17 | +129.01% | 6 | Apr 9, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $76 → $150 | $71.79 | +108.94% | 8 | Mar 31, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $90 → $50 | $8.18 | +511.25% | 4 | Mar 4, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $175 → $85 | $35.89 | +136.87% | 5 | Mar 3, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $190 → $200 | $105.42 | +89.72% | 5 | Feb 19, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $100 → $120 | $39.08 | +207.06% | 5 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $460 → $520 | $493.71 | +5.32% | 3 | Feb 11, 2025 | |
| LRMR Larimar Therapeutics | Initiates: Buy | $18 | $2.37 | +659.49% | 1 | Jan 29, 2025 | |
| ARGX argenx SE | Reiterates: Buy | $660 → $700 | $600.51 | +16.57% | 12 | Jan 14, 2025 | |
| VRNA Verona Pharma | Reiterates: Buy | $44 → $57 | $64.75 | -11.97% | 6 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.67 | +335.97% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $36 | $6.79 | +430.19% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $23.19 | +55.24% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.61 | +396.89% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $13 → $8 | $7.77 | +2.96% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $17 | $9.15 | +85.79% | 7 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $90 | $62.71 | +43.52% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $2.96 | +1,251.35% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 | $25.66 | +367.65% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $109.22 | +83.13% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.82 | +175.48% | 7 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.53 | +409.92% | 1 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $280 | $3.01 | +9,202.33% | 1 | Oct 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $27 → $34 | $20.61 | +64.97% | 1 | Mar 16, 2021 |
Arvinas
Apr 9, 2025
Maintains: Buy
Price Target: $65 → $21
Current: $9.17
Upside: +129.01%
Corcept Therapeutics
Mar 31, 2025
Maintains: Buy
Price Target: $76 → $150
Current: $71.79
Upside: +108.94%
Intellia Therapeutics
Mar 4, 2025
Maintains: Buy
Price Target: $90 → $50
Current: $8.18
Upside: +511.25%
Praxis Precision Medicines
Mar 3, 2025
Maintains: Buy
Price Target: $175 → $85
Current: $35.89
Upside: +136.87%
Axsome Therapeutics
Feb 19, 2025
Maintains: Buy
Price Target: $190 → $200
Current: $105.42
Upside: +89.72%
CRISPR Therapeutics AG
Feb 12, 2025
Maintains: Buy
Price Target: $100 → $120
Current: $39.08
Upside: +207.06%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Buy
Price Target: $460 → $520
Current: $493.71
Upside: +5.32%
Larimar Therapeutics
Jan 29, 2025
Initiates: Buy
Price Target: $18
Current: $2.37
Upside: +659.49%
argenx SE
Jan 14, 2025
Reiterates: Buy
Price Target: $660 → $700
Current: $600.51
Upside: +16.57%
Verona Pharma
Jan 8, 2025
Reiterates: Buy
Price Target: $44 → $57
Current: $64.75
Upside: -11.97%
Jan 8, 2025
Initiates: Buy
Price Target: $16
Current: $3.67
Upside: +335.97%
Nov 12, 2024
Maintains: Buy
Price Target: $17 → $36
Current: $6.79
Upside: +430.19%
Nov 11, 2024
Maintains: Buy
Price Target: $30 → $36
Current: $23.19
Upside: +55.24%
Nov 5, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.61
Upside: +396.89%
Oct 30, 2024
Maintains: Hold
Price Target: $13 → $8
Current: $7.77
Upside: +2.96%
Oct 22, 2024
Maintains: Buy
Price Target: $12 → $17
Current: $9.15
Upside: +85.79%
Sep 17, 2024
Maintains: Buy
Price Target: $118 → $90
Current: $62.71
Upside: +43.52%
Aug 14, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $2.96
Upside: +1,251.35%
Jun 17, 2024
Maintains: Buy
Price Target: $120
Current: $25.66
Upside: +367.65%
Mar 20, 2024
Reiterates: Buy
Price Target: $200
Current: $109.22
Upside: +83.13%
Sep 20, 2023
Maintains: Buy
Price Target: $6 → $5
Current: $1.82
Upside: +175.48%
May 10, 2023
Initiates: Buy
Price Target: $18
Current: $3.53
Upside: +409.92%
Oct 20, 2021
Initiates: Buy
Price Target: $280
Current: $3.01
Upside: +9,202.33%
Mar 16, 2021
Upgrades: Buy
Price Target: $27 → $34
Current: $20.61
Upside: +64.97%